Pembrolizumab (anti-PD-1)

• CAT Number: I043604
• Purity: ≥95%

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1[1][2].
Deferoxamine (Df) chelates pembrolizumab and does not block or alter the binding affinity or specificity of pembrolizumab to CD4+ and CD8+ T cells[2].
Experiments confirmed that 89Zr-Df-Pembrolizumab has a specific activity of 740 mBq/mg antibody. mBq is the unit of radioactivity, used to measure radioactive decay[2].Positron emitter 89Zr-labeled deferoxamine (Df)-Pembrolizumab, through PET imaging, its biodistribution has be dynamically tracked. The results shows that pembrolizumab remained stable in the blood circulation and accumulated most in liver and spleen tissues. And it shows similar biodistribution and pharmacokinetics in mice and rat[2].

Reference

[1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.
 [Content Brief]

[2]. England CG, et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58(1):162-168.
 [Content Brief]